ARCHIVES

In Brief: ACS Board Names McGinnis Prsident; Fuller Re-Elected chairman; Lenhard Is Vice President

This article is from The Cancer Letter archive.

Vol. 20 No. 45 | November 25, 1994

Download PDF Visit The Full Archive

Related Articles

Proposed FDA Charges For NDA Drugs, Biologics Submissions Would Total $76 Million In FY 1990

January 27, 1989

NCI SBIR Offers $10 million in 10 Awards

February 18, 2011

Gynecologic Oncology Group To Conduct Phase III Trial of Xyotax For Ovarian Cancer

April 30, 2004

Survivorship Studies Unfocused As Total Research Increases

November 25, 2011

Standard Procedures Discarded in Review Of $20 Million in Texas Funds For Project Led by Wife of MD Anderson President

May 25, 2012

Drug Development: Tivozanib Trial Discontinued Due to Insufficient Enrollment

February 7, 2014